Turalio FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 6, 2020.
FDA Approved: Yes (First approved August 2, 2019)
Brand name: Turalio
Generic name: pexidartinib
Dosage form: Capsules
Company: Daiichi Sankyo
Treatment for: Tenosynovial Giant Cell Tumor
Turalio (pexidartinib) is a kinase inhibitor indicated for the treatment of symptomatic tenosynovial giant cell tumor (TGCT) in adults.
Development Timeline for Turalio
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.